VA
CLYM

Verdad Advisers’s Climb Bio CLYM Stock Holding History

Verdad Advisers’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$601K Sell
46,115
-98,425
-68% -$1.02M 0.58% 64
2026
Q1 		$990K Buy
+144,540
New +$834K 1.11% 22

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Verdad Advisers's CLYM Position: Q2 2026 in Review

Verdad Advisers reduced its Climb Bio (CLYM) stake by 68% in Q2 2026, selling an estimated $1.02M and leaving 46,115 shares worth $601K. The position accounts for 0.58% of the portfolio, ranked #64.

Verdad Advisers first reported a position in CLYM in Q1 2026 and has held it in 2 quarters since. The position peaked at $990K in Q1 2026. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Verdad Advisers held 46,115 shares of Climb Bio worth $601K as of Q2 2026.
  • Verdad Advisers sold 98,425 Climb Bio shares in Q2 2026, an estimated $1.02M.
  • Climb Bio made up 0.58% of Verdad Advisers's portfolio in Q2 2026, its #64 holding.
  • Verdad Advisers first reported a position in Climb Bio in Q1 2026 and has held it in 2 quarters since.
  • Verdad Advisers's Climb Bio position peaked at $990K in Q1 2026.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.